Tuesday, August 14, 2012

Diovan (Diovan + Diovan HCT) Post Patent Expiry - Equation for Ranbaxy

Post Diovan Patent Expiry in US, Ranbaxy during its six month exclusivity should gross about $100m in sales and $60m (INR 350 crores - ~ 2% of its M.Cap) in net profits.

Diovan Patent will expire on September 21 2012 and Ranbaxy which is the first to file will get a six month Exclusivity.  Diovan including Diovan HCT sells about $2400m annually in the US. Ranbaxy does not have approval for Diovan HCT which comprise more than 60% of Diovan  sales in the US. Mylan has as exclusivity for Diovan HCT.